• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS

Arthritis - Articles and news items

J is for Joint Pain

Blog / 25 November 2016 / Niamh Louise Marriott, Digital Content Producer

J is for Joint Pain – the next instalment of our daily pharmaceutical alphabet bringing you up to date with all the latest in this chronic joint pain research…

NICE recommends secukinumab for people with ankylosing spondylitis

Industry news / 4 August 2016 / National Institute for Health and Care Excellence (NICE)

The National Institute for Health and Care Excellence (NICE) has recommended innovative new drug secukinumab for treating ankylosing spondylitis, a type of arthritis that mainly affects the back….

Samsung Bioepis seeks EU approval for its biosimilar adalimumab candidate, SB5

Industry news / 18 July 2016 / Victoria White, Digital Content Producer

At an estimated $4billion a year, the reference product, Humira, is among the European Union’s largest single drug expenditures…

Cancer immunotherapy drugs linked to autoimmune diseases

Industry news / 24 June 2016 / Victoria White, Digital Content Producer

Some cancer patients taking the immunotherapy drugs ipilimumab and nivolumab may be at a higher-than-normal risk of developing autoimmune diseases…

Bimekizumab demonstrates positive results in patients with psoriatic arthritis

Industry news / 10 June 2016 / Victoria White, Digital Content Producer

In a Phase Ib study, bimekizumab showed fast and sustained efficacy on disease activity measures in both skin and joints and was well-tolerated…

Sirukumab meets both co-primary endpoints in rheumatoid arthritis study

Industry news / 8 June 2016 / Victoria White, Digital Content Producer

The SIRROUND-D study met both co-primary endpoints in evaluating treatment with sirukumab in adult patients with active rheumatoid arthritis…

Novartis plans head-to-head studies of Cosentyx versus Humira

Industry news / 8 June 2016 / Victoria White, Digital Content Producer

Long-term analyses suggest Cosentyx may lead to higher responses than Humira in improving signs and symptoms of ankylosing spondylitis and psoriatic arthritis…

Positive top-line results for tofacitinib citrate in active psoriatic arthritis

Industry news / 8 June 2016 / Victoria White, Digital Content Producer

The OPAL Beyond study met its primary efficacy endpoints demonstrating a statistically significant improvement with tofacitinib 5 mg BID and 10 mg BID…

Infliximab biosimilar Flixabi approved in the EU

Industry news / 31 May 2016 / Victoria White, Digital Content Producer

The EC has granted marketing authorisation in the European Union (EU) for Flixabi, an infliximab biosimilar referencing Remicade…

FDA approves Inflectra (biosimilar infliximab) in the US

Industry news / 6 April 2016 / Victoria White, Digital Content Producer

With this approval, Celltrion’s Inflectra becomes the first biosimilar monoclonal antibody (mAb) medication to receive approval in the US…

Lilly and Incyte announce results from RA-BEACON baricitinib study

Industry news / 31 March 2016 / Victoria White

The study, in patients with rheumatoid arthritis, met its primary endpoint of improved ACR 20 response for baricitinib compared with placebo…

EMA accepts Pfizer’s MAA for Xeljanz in rheumatoid arthritis

Industry news / 24 March 2016 / Victoria White

Xeljanz is the only oral Janus kinase (JAK) inhibitor approved in more than 45 countries around the world for the treatment of moderate to severe RA…

 

Webinar: Use of MicroNIR to optimise fluid bed drying and to reduce waste at tablet compressionWATCH NOW
+ +